Western Standard LLC Reduces Stake in Abeona Therapeutics

Hedge fund lowers holdings in biopharmaceutical company by over 40% in Q3

Feb. 27, 2026 at 1:53pm

Got story updates? Submit your updates here. ›

Western Standard LLC, a hedge fund, reduced its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 40.2% during the third quarter, according to a recent SEC filing. The fund now owns 1,249,957 shares of the biopharmaceutical company's stock, down from 2,091,598 shares previously.

Why it matters

Abeona Therapeutics is a clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare diseases. The reduction in stake by Western Standard LLC could signal a shift in investor sentiment or strategy regarding the company's prospects.

The details

According to the SEC filing, Western Standard LLC sold 841,641 shares of Abeona Therapeutics during the third quarter. The fund now owns approximately 2.44% of the company's outstanding shares, down from 4.08% previously. Abeona Therapeutics is the 11th largest holding in Western Standard LLC's investment portfolio.

  • Western Standard LLC filed the SEC disclosure on February 27, 2026, reporting the stake reduction in the third quarter of 2025.

The players

Western Standard LLC

A hedge fund that has reduced its stake in Abeona Therapeutics by over 40% in the third quarter of 2025.

Abeona Therapeutics Inc.

A clinical-stage biopharmaceutical company focused on developing gene and cell therapies for rare diseases.

Got photos? Submit your photos here. ›

The takeaway

The reduction in stake by Western Standard LLC could signal a shift in investor sentiment or strategy regarding Abeona Therapeutics' prospects, though the reasons behind the move are not explicitly stated. The company's focus on rare disease treatments continues to be a key area of interest for investors in the biopharmaceutical sector.